高亲和度的LilrB2连接体C4d在阿尔茨海默病中升高,并调节突触修剪
Barbara K Brott1, Aram J Raissi1, Kristina D Micheva2
1Departments of Biology and Neurobiology and Bio-X, James H. Clark Center, Stanford University, Stanford, CA 94305.
概括
补充剂C4d蛋白与神经元受体结合,驱动突触修剪. 这种相互作用在衰老和阿尔茨海默氏症中增加.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 突触修剪对于神经电路的发展和整个生命的维护至关重要.
- 人类的白细胞免疫球蛋白样受体类型B2 (LilrB2) 和小鼠的配对免疫球蛋白受体B (PirB),表达在神经元上,并补充蛋白C4已经独立地与突触修剪有关.
- 在神经过程中,C4d的裂变产物C4d在神经过程中的特定功能在很大程度上是未知的.
研究的目的:
- 调查C4d在突触修剪中的功能作用.
- 为了确定C4d是否与神经元受体相互作用,例如LilrB2/PirB.
- 探索C4d受体相互作用对衰老和阿尔茨海默病 (AD) 的影响.
主要方法:
- 评估了C4d与LilrB2/PirB受体的结合亲和力.
- 检查了C4d和LilrB2在人类大脑组织的激发性突触中的局部化,包括阿尔茨海默病 (AD) 样本.
- 在暴露于C4d后,小鼠L5金字塔神经元中树突脊柱密度的量化变化,比较野生型 (WT) 鼠和PirB淘汰赛 (KO) 鼠.
主要成果:
- C4d与高 afinity (纳米) 的LilrB2/PirB受体结合.
- 发现C4d和LilrB2在人类大脑皮层的激发性突触和AD中与β-粉样蛋白共局.
- 随着年龄的增长,C4d和C4的水平会增加,并且在AD时进一步升高.
- 暴露于C4d显著降低了WT小鼠的树突脊柱密度,在PirB KO小鼠中完全取消了这种效应,表明PirB介导了C4d诱导的修剪.
结论:
- 通过与神经元受体 LilrB2/PirB.B. 的相互作用,C4d 在调解突触修剪方面具有意想不到的生理作用.
- C4d-LilrB2/PirB通路代表了一种新的机制,有助于与年龄相关的和AD相关的突触损失.
- 这些发现表明,不同补充级联组件在通过神经元和质通路调节突触修剪方面发挥着协作作用.
更多相关视频
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
Ligand-gated Ion Channels
14.0K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
14.0K
Long-term Depression
3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.1K
Long-term Depression
33.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.1K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


